drugset / Trial / NCT00036179

Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis

NCT00036179

Phase 2 Completed 75 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety and efficacy of FK463 in the treatment of patients with confirmed candidemia or invasive candidiasis.

Timeline

Start
1999-02-27
Primary completion
2002-01-27
Completion
2002-01-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Micafungin Peptide Intravenous

Indications